Latest news with #SpyreTherapeutics
Business Insider
22-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sandoz Group Ltd (SDZXF – Research Report) and Spyre Therapeutics (SYRE – Research Report) with bullish sentiments. Confident Investing Starts Here: Sandoz Group Ltd (SDZXF) In a report issued on June 20, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed last Tuesday at $51.98. Pauillac has an average return of 32.9% when recommending Sandoz Group Ltd. According to Pauillac is ranked #1277 out of 9634 analysts. Sandoz Group Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $50.74, a -2.4% downside from current levels. In a report issued on June 9, Barclays also maintained a Buy rating on the stock. Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics today and set a price target of $71.00. The company's shares closed last Friday at $15.01. According to CFA is a 1-star analyst with an average return of -3.4% and a 43.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, which is a 277.9% upside from current levels. In a report issued on June 17, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target.
Globe and Mail
19-06-2025
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE – Research Report) and UnitedHealth (UNH – Research Report) with bullish sentiments. Confident Investing Starts Here: Spyre Therapeutics (SYRE) BTIG analyst Julian Harrison maintained a Buy rating on Spyre Therapeutics yesterday and set a price target of $70.00. The company's shares closed last Tuesday at $15.18. According to Harrison is a 3-star analyst with an average return of 1.1% and a 41.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Rani Therapeutics Holdings, and Mereo Biopharma Group Plc. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, implying a 237.1% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target. UnitedHealth (UNH) Bernstein analyst Lance Wilkes assigned a Buy rating to UnitedHealth yesterday and set a price target of $377.00. The company's shares closed last Tuesday at $308.87. According to Wilkes is a 2-star analyst with an average return of 0.0% and a 41.3% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. ;'> Currently, the analyst consensus on UnitedHealth is a Moderate Buy with an average price target of $367.68, representing a 19.6% upside. In a report issued on June 2, KeyBanc also maintained a Buy rating on the stock with a $400.00 price target.
Yahoo
06-06-2025
- Business
- Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 50,200 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on June 2, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted with a 10-year term and an exercise price equal to $15.40, the closing price per share of Spyre's common stock as reported by Nasdaq on June 2, 2025. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee's start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at View original content to download multimedia: SOURCE Spyre Therapeutics, Inc.
Washington Post
27-02-2025
- Business
- Washington Post
Spyre Therapeutics: Q4 Earnings Snapshot
WALTHAM, Mass. — WALTHAM, Mass. — Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $56.3 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss of 81 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.10 per share.
